Transparency data: Non-tech summaries 2016: projects on cardiovascular disorders

Home Office Building - London - by .Martin. via Flickr



This document outlines the projects granted under the Animals (Scientific Procedures) Act 1986 during 2016 with a primary purpose of translational applied research – human cardiovascular disorders.

  • analysing signalling gene function in the heart (heart, electrophysiology, hypertrophy, arrhythmias)

  • mechanisms of innate immunity in cardiovascular disease (heart disease, immune system)

  • prevention of chronic heart failure (heart failure, myocardial infarction, diabetes, hypercholesterinaemia)

  • genetic and bioenergetic determinants of cardiac arrhythmias (arrhythmias, heart disease, sudden death, genetics)

  • autonomic control of the cardiovascular system (cardiovascular disease, autonomic control)

  • the effects of myocardial infarction (myocardial infarction)

  • preclinical therapies for pulmonary hypertension (cardiovascular, pulmonary, genetics, therapy)

  • pathophysiology of the cardiovascular system (metabolic syndrome; obesity; heart function; atherosclerosis)

  • comparative cardiovascular homeostasis (transgenics; hypertension; metabolism; kidney)

  • mechanisms of progressive cardiac dysfunction (heart failure, hypertrophy, cardiac remodelling)

  • pathophysiology of heart failure (heart failure, calcium, β-adrenergic, ultrastructure)

  • cardiac injury, repair, regeneration & remodelling (heart attack, drug therapy, heart failure)

  • dietary vascular protection in utero and stroke (stroke, obesity, pregnancy, risk, diabetes)

  • mechanisms of thrombosis and atherosclerosis (macrophages, endothelial cells, inflammation, atherosclerosis, thrombosis, cardiovascular disease)

  • investigating the genetics of cardiovascular disease (hypertension, organ-damage, rats, mice, genetics)

  • investigating a novel treatment for heart failure (perhexiline, metabolism, hypertrophy, heart failure)

  • small animal models of cardiovascular disease (ischaemia, therapy, cardiovascular disease)

  • regulation of thrombosis and haemostasis and its influence on cardiovascular diseases (clot, thrombosis, stroke, atherosclerosis, vessel wall)

  • pathogenesis and therapy of vascular diseases (atherosclerosis; aneurysm; angiogenesis; cell therapy; cardiovascular diseases intervention.)

  • rodent models of arteriosclerosis (arteriosclerosis, stem cells, endothelial cells, vessel graft)

  • role of nitric oxide and reactive oxygen species in cardiac function (nitric oxide, reactive oxygen species, heart failure, diabetes, atrial fibrillation)

  • rodent models of pulmonary hypertension and associated co-morbidities (pulmonary hypertension, pulmonary vascular remodelling, right heart failure)

  • vascular protective genes in angiogenesis (vascular, preeclampsia, hydrogen sulphide, heme oxygenase, pregnancy)

  • myocardial infarction and heart failure (heart, failure, infarction, protection, injury)

  • angiogenesis, microcirculation and microenvironment (angiogenesis, microcirculation, tumour growth, wound-healing, vascular-targeted)

  • protecting and repairing the diseased heart (heart attack, cardiac surgery, ischemia reperfusion injury)

  • factors affecting valve development and disease (veins, lymphatics, heart)

  • studies of complex genetic traits in rats (rat, cardiovascular, metabolic, kidney genetics)

  • mechanistic studies in pre-clinical stroke/small vessel disease (stroke, small vessel disease, hypertension, rats, mice)

  • understanding and treating cardiovascular disease (cardiovascular development, heart repair)

  • the molecular basis of cardio-metabolic disease (diabetes, cardiovascular disease, insulin resistance, insulin-like growth factors, atherosclerosis)

  • myocardial infarction (heart attack, vascular dysfunction, nitrite, nitric oxide, perhexiline)

  • calcium-permeable channels and their associated mechanisms and therapeutic potential (blood vessel, cardiovascular disease, cancer, diabetes, calcium channels)

  • improving minimally invasive treatment of coronary artery disease (coronary, artery, atherosclerosis, angioplasty, stents)

  • targeting the immune response in cardiovascular diseases (atherosclerosis; restenosis; aneurysm; myocardial infarction; stroke)

  • innovative treatments for heart failure (heart failure, stem cell therapy, gene therapy, drug therapy)

  • ischaemia-reperfusion injury and shock (ischaemia, shock, kidney, haemorrhage, heart research, trauma)

  • the long-term effects of prenatal hypoxia on cardiomyocyte function (programming, pre-natal hypoxia, cardiac, mitochondria, myocyte)

  • Be the first to comment

    Leave a Reply